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Abstract Hepatitis C virus (HCV) exhibits a narrow host
range and a specific tissue tropism. Mice expressing major
entry receptors for HCV permit viral entry, and therefore
the species tropism of HCV infection is considered to be
reliant on the expression of the entry receptors. However,
HCV receptor candidates are expressed and replication of
HCV-RNA can be detected in several nonhepatic cell lines,
suggesting that nonhepatic cells are also susceptible to
HCV infection. Recently it was shown that the exogenous
expression of a liver-specific microRNA, miR-122, facili-
tated the efficient replication of HCV not only in hepatic
cell lines, including Hep3B and HepG2 cells, but also in
nonhepatic cell lines, including Hec1B and HEK-293T
cells, suggesting that miR-122 is required for the efficient
replication of HCV in cultured cells. However, no infec-
tious particle was detected in the nonhepatic cell lines, in
spite of the efficient replication of HCV-RNA. In the
nonhepatic cells, only small numbers of lipid droplets and
low levels of very-low-density lipoprotein-associated pro-
teins were observed compared with findings in the hepatic
cell lines, suggesting that functional lipid metabolism
participates in the assembly of HCV. Taken together, these
findings indicate that miR-122 and functional lipid
metabolism are involved in the tissue tropism of HCV
infection. In this review, we would like to focus on the role
of miR-122 and lipid metabolism in the cell tropism of
HCV.
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Introduction
More than 170 million individuals worldwide are chroni-
cally infected with hepatitis C virus (HCV), and the cir-
rhosis and hepatocellular carcinoma (HCC) induced by
HCV infection are life-threatening diseases [1]. On the
other hand, HCV infection sometimes induces extra-hepatic
manifestations (EHM), including mixed cryoglobulinemia
and non-Hodgkin lymphoma [2–5]. The mechanisms of the
pathogenesis and cell tropism of HCV have not been fully
elucidated yet owing to the lack of an appropriate infection
model. Although chimpanzees are susceptible to HCV
infection, the use of these animals to study experimental
infection is ethically problematic, and no other animal
model with susceptibility to HCV infection has been
established [6]. Furthermore, robust in vitro HCV propa-
gation has been limited to the combination of cell-culture-
adapted clones based on the genotype 2a JFH1 strain
(HCVcc) and human liver cancer-derived Huh7 cells [7, 8].
The expression of a liver-specific microRNA, miR-122, has
been shown to dramatically enhance the translation and
replication of HCV-RNA [9]. Recently, several reports
have shown that the exogenous expression of miR-122
facilitates the efficient replication of viral RNA in several
hepatic and nonhepatic cell lines [10–13]. Of note, the
clinical application of a specific inhibitor of miR-122 to
chronic hepatitis C patients is now in progress [14]. In
addition, it has been shown that liver-specific expression of
very-low-density lipoprotein (VLDL)-associated proteins
is involved in the assembly of infectious HCV particles
[15, 16]. This review will focus on the role of miR-122
expression and lipid metabolism in HCV infection.
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microRNA and virus infection
miRNAs were first identified by Lee et al. [17] and since
that time a great number of miRNAs have been registered
in the miRNA database. miRNA incorporated into RNA-
induced silencing complex (RISC) interacts with a target
mRNA via a specific recognition element. RISC contains
argonaute 2 (Ago2), Dicer, and TAR RNA binding protein
(TRBP) [18, 19]. In humans, Ago2 plays a pivotal role in
the repression of translation of target genes [20]. It is now
commonly believed that miRNAs play important roles in
cell homeostasis, and that abnormality of miRNA expres-
sion participates in the development of several diseases,
including viral infections [18, 19]. miRNAs encoded by
Epstein–Barr virus (EBV) were identified in 2004 [4, 21],
and over 200 viral miRNAs have been reported in several
DNA viruses, especially in herpesviruses [22, 23]. Previous
reports have shown that viral miRNAs participate in viral
propagation by regulating the host gene expression [22,
23]. Many viral miRNAs suppress the host gene expression
involved in innate and acquired immunities and enhance
viral propagation [22, 24, 25]. Most RNA viruses replicate
in the cytoplasm, and thus it had been believed that RNA
viruses do not encode viral miRNAs. Rouha et al. [26]
showed that an RNA virus, the tick-borne encephalitis
virus, is capable of producing functional miRNA by the
insertion of an miRNA element into viral RNA. Actually, it
has been shown that virus-derived small RNAs emerge by
infection with RNA viruses, including influenza virus and
West Nile virus [27, 28]. These data suggest that both viral-
encoded and host gene-derived miRNAs are involved in
the regulation of viral propagation.
Liver-specific microRNA, miR-122
miR-122 is a liver-specific microRNA and is the micro-
RNA most abundantly expressed in the liver [29–31].
Although Li et al. [32] have suggested that hepatocyte
nuclear factor 4 alpha (HNF4A) positively regulates the
expression of miR-122, the details on the tissue specificity
of miR-122 expression have not been fully elucidated yet.
miR-122 targets the 30untranslated region (30UTR) of the
mRNAs of cytoplasmic polyadenylation element binding
protein (CPEB), hemochromatosis (Hfe), hemojuverin
(Hjv), disintegrin, and metalloprotease family 10
(ADAM10) and represses their translation [33–35]. miR-
122 activates the translation of p53 mRNA through the
suppression of CPEB and participates in cellular senes-
cence [33]. Through the inhibition of Hfe and Hjv, miR-
122 participates in iron metabolism [34]. Esau et al. [36]
showed that miR-122 positively regulated lipid metabolism
through the reduction of the mRNAs of lipid-associated
proteins, and that inhibition of miR-122 expression atten-
uated liver steatosis in high-fat-fed mice, suggesting that
miR-122 may be an attractive therapeutic target for meta-
bolic diseases. miR-122 has also been shown to be
involved in the propagation of hepatitis viruses, including
hepatitis B virus (HBV) and HCV [9, 37, 38]. Wang et al.
[38] have revealed that miR-122 suppresses cyclin G1, and
this factor is known to enhance the replication of HBV by
inhibiting the binding of p53 to HBV enhancer elements. In
other reports, a low level of miR-122 expression in plasma
was significantly associated with the incidence of HBV-
related HCC [39]. These results suggest that miR-122
expression inhibits the propagation and pathogenesis of
HBV. On the other hand, miR-122 expression enhances the
propagation of HCV through genetic interaction with the
50UTR of the HCV genome [9]. It is interesting to note that
the effects of miR-122 expression on viral propagation are
different between HBV and HCV.
miR-122 expression and HCV infection (Fig. 1)
Jopling et al. [9] reported for the first time that the inhi-
bition of miR-122 dramatically decreased RNA replication
in HCV replicon cells harboring subgenomic (SGR) or
fullgenomic (FGR) viral RNA. They identified the 21
nucleotide (nt) of the miR-122 binding site in the 50 end of
the 50UTR of HCV RNA. In addition, lack of enhancement
of HCV replication by the expression of a mutant miR-122
incapable of binding to the 50UTR was canceled by the
introduction of a complementary mutation in the 50UTR,
suggesting that direct interaction of miR-122 with the
50UTR is crucial for the enhancement of HCV replication.
In subsequent reports, they identified a second adjacent
miR-122 binding site in the 50UTR [40]. Furthermore,
ectopic expression of the mutant miR-122 rescued the
replication of an HCV RNA possessing mutations in both
miR-122 binding sites, suggesting that the interaction of
miR-122 with both sites in the 50UTR is required to aug-
ment viral replication. In addition, Machlin et al. [41] have
revealed that not only the seed sequence but also nucleo-
tides located at the positions of 15 and 16 in miR-122 are
required for the enhancement of HCV replication. Inter-
estingly, nucleotides 15 and 16 are not required for the
conventional microRNA function of miR-122, suggesting
that the conventional machinery of miR-122 is not
involved in the miR-122-dependent enhancement of HCV
replication. A recent study showed that the interaction of
miR-122 with the 50UTR of HCV was also required for the
efficient production of infectious particles in cell culture
[42].
Although the precise mechanisms of the miR-122-
mediated enhancement of HCV replication have not been
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fully elucidated yet, Henke et al. [43], by using poly-
merase defective viral RNA, showed that miR-122 stim-
ulated the translation of HCV RNA by enhancing the
association of ribosomes at an early initiation stage. They
concluded that miR-122 might contribute to HCV liver
tropism at the level of translation. Wilson et al. [44]
showed that knockdown of Ago2 in SGR cells and
HCVcc-infected cells attenuated HCV replication, and
that knockdown of Ago2 also reduced the translation of
the polymerase defective HCV RNA. Shimakami et al.
[45] showed that miR-122 stabilized viral RNA and
reduced its decay in concert with Ago2, and that miR-
122-dependent stabilization of HCV RNA was not
observed in Ago2-knockout murine embryonic fibroblasts.
These results suggest that Ago2 is required for the effi-
cient enhancement of both the translation and replication
of HCV. On the other hand, Machlin et al. [41] have
suggested that the 30 overhang binding of miR-122 to the
50 end of the HCV genome participates in circumvention
from the recognition by the cytoplasmic RNA sensor,
RIG-I. It is feasible to speculate that miR-122 has other
functions in the HCV life cycle, in addition to the sta-
bilization of viral RNA and evasion from the host’s innate
immune response.
Establishment of new permissive cell lines for HCV
propagation by the expression of miR-122
The lack of immunocompetent small animal models and
cell culture systems to support the propagation of HCV in
patient sera has hampered both the understanding of the
HCV life cycle and the development of antiviral drugs
[46]. HCV replicon cells in which the HCV genome
autonomously replicates, and pseudotype viruses bearing
HCV E1 and E2 glycoproteins were established to assess
viral replication and entry, respectively [47, 48]. After-
wards, an infectious HCV derived from the JFH1 strain of
genotype 2a (HCVcc) was developed [7, 8]. On the basis of
the data obtained from these in vitro systems, the HCV life
cycle has been clarified, and host factors involved in HCV
propagation have been identified as therapeutic targets for
chronic hepatitis C [46]. However, the robust propagation
of HCVcc in well-characterized human liver cell lines
other than Huh7 had not been successful until recently.
Chang et al. [49] showed that the exogenous expression of
miR-122 facilitated the replication of HCV RNA in kid-
ney-derived HEK-293 cells. In addition, Lin et al. have
demonstrated that the expression of miR-122 and depletion
of interferon regulatory factor 3 (IRF-3) permit replication
Fig. 1 miR-122 enhances the translation of hepatitis C virus (HCV)
RNA. Primary miRNA (pri-miRNA) transcribed by RNA polymerase
II in the nucleus is processed into precursor miRNA (pre-miRNA) by
Drosha and DiGeorge syndrome critical region protein 8 (DGCR8).
Pre-miRNA is exported into the cytoplasm by nucleocytoplasmic
shuttle protein exportin 5, processed to 22nt by dicer, and then
incorporated into argonaute proteins to form the RNA-induced
silencing complex (RISC). The passenger strand of miRNA (blue)
is degraded and the guide strand (red) is matured in the RISC.
Generally, miRNA represses the translation of host mRNA by binding
to its 3’untranslated region (30UTR). In contrast, liver-specific miR-
122 binds to two sites in the 50UTR of the HCV genome and enhances
its translation and replication. GTP Guanosine-5-triphosphate, IRES
internal ribosomal entry site
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of the HCV genome in mouse fibroblasts [50]. These
results suggest that the expression of miR-122 might
facilitate the efficient replication of HCVcc not only in
hepatic cells but also in nonhepatic cells. In fact, the
expression level of miR-122 in Huh7 cells has been shown
to be higher than that in other hepatic cell lines, including
Huh6, HepG2, and Hep3B cells [10]. Recently, two groups
reported that miR-122 expression facilitated the efficient
propagation of HCVcc in human hepatic cell lines [10, 11].
Narbus et al. [11] showed that HepG2 cells stably
expressing CD81 and miR-122 supported efficient repli-
cation and the production of infectious particles. Interest-
ingly, internal ribosomal entry site (IRES)-dependent
translation of HCV exhibited a slight (1.4–2.1-fold)
increase by the expression of miR-122 in HepG2 cells
compared with that in parental cells, suggesting that miR-
122 is required for efficient RNA replication but not in
translation in HepG2 cells upon infection with HCVcc.
Kambara et al. [10] established a novel permissive cell line
for the propagation of HCVcc by the expression of miR-
122 in Hep3B cells. miR-122 expression facilitated the
efficient propagation of HCVcc and the establishment of
HCV replicon cells in Hep3B cells. In addition, ‘‘cured’’
Hep3B cells established by the elimination of HCV RNA
from the Hep3B replicon cells facilitated the efficient
propagation of HCVcc compared to parental cells. Inter-
estingly, the expression of miR-122 in the ‘‘cured’’ Hep3B
cells was significantly higher than that in the parental cells.
In addition, Ehrhadt et al. [51] have shown that the
expression levels of miR-122 in Huh7-derived cured cells,
including Huh7.5 and Huh-Lunet cells, are significantly
higher than those in parental Huh7 cells. Collectively, these
results suggest that miR-122 is a key determinant of the
efficient replication of HCVcc in hepatic cell lines.
Expression of miR-122 facilitates the efficient
replication of HCV in nonhepatic cells
In clinical studies, negative strands of HCV genome have
been detected in nonhepatic tissues of chronic hepatitis C
patients, suggesting the possibility of extrahepatic propa-
gation of HCV [52–56]. In addition, HCV replication was
detected in peripheral blood mononuclear cells (PBMCs)
of patients with occult HCV infection [57]. Roque-Afonso
et al. [52] showed that highly divergent variants of HCV
were detectable in PBMCs, but not in plasma or in liver,
suggesting the possibility of the extrahepatic propagation
of HCV. Furthermore, previous reports have suggested that
recurrences of HCV infection after antiviral treatment or
liver transplantation were attributable to chronic infection
of HCV in extrahepatic tissues [58]. Collectively, these
results might suggest a correlation between extrahepatic
HCV replication and the development of EHM, including
mixed cryoglobulinemia and non-Hodgkin lymphoma,
which are frequently observed in chronic hepatitis C
patients. However, details of the extrahepatic propagation
of HCV have not been studied owing to the lack of an
appropriate experimental model [59, 60].
HCV replicon cells have been established in several
nonhepatic cell lines. Kato et al. [61] established JFH1-
based SGR cells by using HeLa and HEK293 cells, sug-
gesting that the HCV genome can replicate in nonhepatic
cells. In addition, Fletcher et al. [62] showed that brain
endothelial cells supported HCV entry and replication,
suggesting that HCV infection in the central nervous sys-
tem participates in HCV-associated neuropathologies.
Given the marked effects of miR-122 expression on the
propagation of HCVcc in hepatic cell lines, we hypothe-
sized that the expression of miR-122 in nonhepatic cell
lines would facilitate the establishment of novel permissive
cell lines for HCV. Recently, we have shown that Hec1B
cells derived from the human uterus exhibited a low level
of viral replication and the exogenous expression of miR-
122 significantly enhanced replication upon infection with
HCVcc [63]. In addition, an miR-122-specific inhibitor for
miR-122 called locked nucleic acid (LNA-miR-122)
inhibited the enhancement of HCVcc replication in Hec1B
cells expressing miR-122, while the basal replication of
HCVcc in parental Hec1B cells was resistant to the treat-
ment. These results suggest that Hec1B cells permit HCV
replication in an miR-122-independent manner and the
exogenous expression of miR-122 enhances viral replica-
tion. In this report, cured Hec1B cells established by the
elimination of HCV RNA from Hec1B replicon cells
exhibited more potent replication of HCVcc than the
parental cells. As seen in the cured Hep3B cells, the
expression levels of miR-122 in the Hec1B cured cells
were significantly higher than those in the parental cells
[63]. Taken together, these results show that the expression
of miR-122 facilitates the replication of HCVcc in non-
hepatic cells.
Viral assembly in nonhepatic cells
Previous reports have shown that the production of VLDL
is involved in the formation of infectious HCV particles
[15, 16]. Apolipoprotein B (ApoB), apolipoprotein E
(ApoE), and microsomal triglyceride transfer protein
(MTTP) have major roles in the secretion of VLDL.
Gastaminza et al. [15] have demonstrated that ApoB and
MTTP are cellular factors essential for the efficient
assembly of infectious HCV particles. They concluded that
HCV acquired hepatocyte tropism through utilization of
the VLDL secretory pathway. On the other hand, studies by
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other groups have demonstrated that infectious HCV par-
ticles are highly enriched in ApoE, which is a major
determinant of HCV infectivity and production [64]. In
their reports, small interfering RNA (siRNA)-mediated
knockdown of ApoB and treatment with MTTP inhibitors
exhibited no significant effect on the infectivity and pro-
duction of HCV, suggesting that ApoE but not ApoB is
required for viral assembly. In addition, Mancone et al.
[65] have shown that apolipoprotein A-I (ApoA-I) is
required for the replication of HCV and the production of
infectious particles. Collectively, these results suggest that
several VLDL-associated proteins are involved in HCV
assembly.
In our recent report, the viral assembly process was
shown to be impaired in nonhepatic cells exogenously
expressing miR-122, in spite of the efficient replication of
the HCV genome [63]. Interestingly, low but substantial
infectious titers were detected in hepatic Hep3B cells upon
infection with HCVcc, even though the RNA replication
was lower than that in nonhepatic Hec1B cells expressing
miR-122. The expression levels of VLDL-associated pro-
teins, including ApoE, ApoB, and MTTP, in nonhepatic
cell lines were significantly lower than those in hepatic cell
lines, suggesting that lack of expression of VLDL-associ-
ated proteins is one of the reasons for the inability of
nonhepatic cells to produce infectious particles. Miyanari
et al. [66] showed that lipid droplets (LDs) were required
for the formation of infectious particles via interaction
between the core protein and viral RNA. Interestingly, only
a small amount of LDs was detected in nonhepatic cells,
including Hec1B and HEK293T cells, compared with the
amount in hepatic cell lines, suggesting that a low level of
LD formation is also involved in the impairment of
infectious particle formation in nonhepatic cells [63].
Taken together, these findings suggest the possibility that
the reconstitution of functional lipid metabolism in non-
hepatic cells facilitates the production of infectious
particles.
Tropism of HCV infection
In many cases, the cell tropism of viral infection is defined
by the expression of virus-specific receptors. The expres-
sion of CD4 and chemokine receptors has an important role
in the determination of the lymphotropism of human
immunodeficiency virus infection [67]. In measles virus
infection, the signaling lymphocyte activation molecule is
a determinant of lymphotropism [68, 69]. Previous reports
have shown that human CD81, scavenger receptor class B1
(SR-B1), Claudin1 (CLDN1), and Occludin (OCLN) are
crucial for HCV entry [70–73]. Although murine cells
cannot permit HCV entry, the exogenous expression of
human-derived receptor candidates in murine cells has
been shown to facilitate HCV entry, suggesting that HCV-
specific receptors participate in the determination of the
cell tropism of HCV [74, 75]. However, previous reports
have also revealed that HCV receptor candidates were
highly expressed in many nonhepatic tissues [62, 76], and
our recent report has demonstrated that many nonhepatic
cells permit the entry of HCV pseudotypes [63]. In addi-
tion, many reports have suggested the possibility of HCV
replication in extrahepatic sites such as PBMCs and neu-
ronal cells [55, 62], suggesting that host factors other than
receptors could be involved in the tissue tropism of HCV.
Although previous reports have shown that host factors
such as VAMP-associated protein (VAP)-A, VAP-B,
cyclophilin A, FK506 binding protein 8, and heat shock
protein 90 participate in HCV replication, these molecules
are unlikely to participate in the determination of the liver
tropism of HCV, owing to their ubiquitous expression
[46, 77–79]. As described above, miR-122 is abundantly
expressed specifically in hepatocytes and is essential for
the efficient replication of HCV. In addition, a recent report
showed that hepatocyte-like cells derived from induced
pluripotent stem cells (iPSCs) expressed high levels of
miR-122 and supported the entire life cycle of HCVcc,
suggesting that miR-122 might be one of the most critical
determinants of the liver tropism of HCV infection
[80, 81]. On the other hand, VLDL-associated proteins,
Fig. 2 HCV replication in hepatocytes and nonhepatic cells. Chronic
HCV infection induces liver cirrhosis and hepatocellular carcinoma
(HCC), and is also often associated with the development of
extrahepatic manifestations (EHM) such as malignant lymphoma
and autoimmune diseases. Not only hepatocytes but also nonhepatic
cells express major HCV receptors, including CD81, SR-BI, CLDN1,
and OCLN. In hepatocytes, functional expression of miR-122 and
lipid metabolism facilitate the efficient propagation of HCV. In
contrast, the lack of expression of miR-122 and very-low-density
lipoprotein (VLDL)-associated proteins might be associated with the
incomplete propagation of HCV in nonhepatic cells. Low levels of
HCV replication in nonhepatic cells may participate in the develop-
ment of EHM
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including ApoB, ApoE, and MTTP, are specifically
expressed in hepatic cells, and no infectious particles are
produced in nonhepatic cells such as Hec1B and 293T-
CLDN cells [63]. Collectively, these data suggest that the
VLDL-producing system is involved in the liver tropism of
HCV.
Although HCV can internalize not only into hepatocytes
but also into nonhepatic cells through receptor-mediated
endocytosis, miR-122 expression and functional lipid
metabolism in hepatocytes facilitate the efficient replica-
tion and assembly of HCV (Fig. 2). On the other hand, lack
of expression of miR-122 and VLDL-associated proteins
might be associated with the incomplete propagation of
HCV in nonhepatic cells (Fig. 2).
Conclusion
Recent progress in HCV research has revealed that the
tissue tropism of HCV is reliant on the expression of liver-
specific miR-122 and a functional lipid metabolism rather
than being reliant on the expression of entry receptors.
However, the molecular mechanisms of the enhancement
of viral replication induced by the interaction of miR-122
with the 50UTR of HCV and the assembly of viral particles
via VLDL-producing machinery remain unknown. In
addition, the participation of nonhepatic cells in the
development of EHM has been suggested, through an
incomplete or low level of HCV replication. Elucidation of
the liver tropism of HCV will provide a clue to the
development of new antiviral drugs for the treatment of
chronic hepatitis C and could lead to an understanding of
the pathogenesis of EHM induced by HCV infection.
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